Israel’s Pharma Two B (see here in 2015) has successfully completed the Phase 3 human trial of its P2B001 treatment for Parkinson’s Disease. The trial met its primary and key secondary endpoints, and the company can now prepare for US FDA approval.

https://www.jpost.com/health-and-wellness/article-689352